Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

578
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
578
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

704
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
704
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

677
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
677
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

551
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
551
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.1K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.1K
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

658
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
658

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Direct, transapical, echocardiography-guided laceration of an Alfieri stitch to facilitate transcatheter mitral valve implantation: Keeping it simple.

JTCVS structural and endovascular·2026
Same author

Stem-Cell-Derived Biologic Ventricular Assist Tissue in Heart Failure.

The New England journal of medicine·2026
Same author

Manual long axis strain compared to automated feature-tracking deformation imaging for identification of masked left heart involvement in pulmonary hypertension.

The international journal of cardiovascular imaging·2026
Same author

Impact of a Clinical Valve Coordinator on Hospital Length of Stay and Patient Outcomes: Results From the BENCHMARK Registry.

Structural heart : the journal of the Heart Team·2026
Same author

Calculation of pulmonary capillary wedge pressure including left atrial function is superior to morphology alone and accurately identifies elevated filling pressures in left heart disease.

Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance·2025
Same author

Right Atrial Contraction Strain Is Associated With Clinically Significant Cellular Rejection in Patients After Heart Transplantation.

Transplant international : official journal of the European Society for Organ Transplantation·2025

Related Experiment Video

Updated: Mar 3, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.3K

[Update on hypertrophic cardiomyopathy].

Andreas J Rieth1, Tim Seidler2

  • 1Abteilung Kardiologie, Kerckhoff-Klinik, Benekestr. 2-8, 61231, Bad Nauheim, Deutschland. a.rieth@kerckhoff-klinik.de.

Innere Medizin (Heidelberg, Germany)
|March 2, 2026
PubMed
Summary
This summary is machine-generated.

Hypertrophic cardiomyopathy (HCM) includes genetic and acquired forms. Diagnosis involves imaging and genetic testing, with risk stratification and targeted treatments available for primary HCM and transthyretin amyloid cardiomyopathy.

Keywords:
Amyloid cardiomyopathyHeart failureHypertrophic cardiomyopathy/differential diagnosisLeft ventricular outflow tract obstructionMyosin inhibition

More Related Videos

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

6.3K
Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

18.0K

Related Experiment Videos

Last Updated: Mar 3, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.3K
An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

6.3K
Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

18.0K

Area of Science:

  • Cardiology
  • Genetics
  • Medical Imaging

Background:

  • Hypertrophic cardiomyopathy (HCM) in Europe encompasses primary genetic and secondary acquired forms.
  • Distinguishing between these forms is crucial for appropriate management.
  • Left ventricular wall thickening necessitates a differential diagnosis to identify the underlying cause.

Purpose of the Study:

  • To outline the diagnostic approach for hypertrophic cardiomyopathy (HCM).
  • To highlight the role of advanced imaging and genetic testing in HCM diagnosis.
  • To discuss current therapeutic strategies for different HCM subtypes.

Main Methods:

  • Echocardiography for initial assessment of left ventricular wall thickening.
  • Cardiac magnetic resonance imaging (CMR) for definitive diagnosis.
  • Genetic testing for identifying primary HCM causes.
  • Risk stratification for arrhythmias in primary HCM patients.

Main Results:

  • CMR is key for definitive HCM diagnosis.
  • Genetic testing is important for primary HCM, especially common forms.
  • Arrhythmia risk stratification is mandatory for primary HCM.
  • Specific treatments exist for symptomatic obstruction and transthyretin amyloid cardiomyopathy.

Conclusions:

  • A systematic diagnostic pathway involving echocardiography, CMR, and genetic testing is essential for HCM.
  • Risk stratification and targeted therapies improve outcomes for primary HCM and secondary forms like transthyretin amyloid cardiomyopathy.